Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
Legend Biotech (NASDAQ: LEGN) announced that CEO Ying Huang, Ph.D. will present company updates at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) announced that CEO Ying Huang, Ph.D. will present company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT.
The presentation will be available via a live webcast on Legend Biotech's Investor Relations website, and a replay will be posted approximately 48 hours after the live event.
Details
News Market Reaction – LEGN
On Dec 17, the day this news came out, LEGN closed 1.06% below the previous close.
Data tracked by StockTitan Argus for the Dec 17 session.
Key Figures
- Conference date
- January 14, 2026
- J.P. Morgan Healthcare Conference presentation
- Presentation time
- 9:00 a.m. PT
- Scheduled LEGN presentation slot
- Webcast replay delay
- 48 hours
- Approximate time until replay becomes available
Historical Context
-
Opened new 31,000-square-foot Philadelphia cell therapy R&D facility.
-
Reported strong CARVYKTI sales and about $1.0B cash/time deposits.
-
Announced 10 ASH presentations including CARVYKTI and Lucar-G39D data.
-
Scheduled investor call to review third quarter 2025 results.
-
Planned CEO fireside chat at Morgan Stanley Global Healthcare Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cell therapy medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14th, 2026, at 9:00 a.m. PT.
The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.
ABOUT LEGEND BIOTECH
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
media@legendbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.